16 March 2016 - Consumers and health professionals are advised that the TGA is investigating a significant safety concern involving idelalisib 100 mg and 150 mg tablets, which are marketed in Australia as Zydelig.

For more details, go to: http://www.tga.gov.au/monitoring-communication/idelalisib-zydelig-100-mg-and-150-mg-tablets